
|Articles|January 1, 2005
Trials set for dual-optic accommodating IOL
Irvine, CA-The FDA has approved Visiogen Inc.'s Investigational Device Exemption (IDE) for the Synchronym dual-optic accommodating IOL.
Advertisement
Irvine, CA-The FDA has approved Visiogen Inc.'s Investigational Device Exemption (IDE) for the Synchronym dual-optic accommodating IOL.
The company plans to begin U.S. clinical trials in 2005 on what it calls the first lens of its kind.
The company also has developed a pre-loaded injector for delivery of the lens, which can be inserted through a small incision. Trials outside the U.S. will begin in 2005, according to Luis Vargas, MD, the company's medical director.
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Ophthalmology pipeline watch: Key trial results and PDUFA dates for Q1 2026
2
Rayner announces Sophi Phaco System in the US
3
PRIMA retinal implant restores vision in patients with advanced GA
4
Q&A: Evolving approaches to geographic atrophy management
5














































